© 2001 by Oxford University Press
Journal of the National Cancer Institute, Vol. 93, No. 5, 382-387,
March 7, 2001
© 2001 Oxford University Press
REPORT |
Effect of Antiangiogenic Therapy on Slowly Growing, Poorly Vascularized Tumors in Mice
Affiliations of authors: W.-D. C. Beecken, A. Fernandez, A. M. Joussen, E.-G. Achilles, E. Flynn, K. Javaherian, J. Folkman, Y. Shing, Department of Surgery, Children's Hospital, and Harvard Medical School, Boston, MA; K.-M. Lo, S. D. Gillies, Lexigen Pharmaceuticals Corp., Lexington, MA.
Correspondence to: Judah Folkman, M.D., Children's Hospital, Hunnewell 103, 300 Longwood Ave., Boston, MA.
Background: Angiogenesis is essential for tumor growth and progression. Therefore, inhibition of angiogenesis is being studied as a new anticancer therapy. Because cytotoxic chemotherapy is more effective on rapidly growing tumors than on slowly growing tumors, it has been assumed that antiangiogenic therapy will also be effective only on rapidly growing, highly vascularized tumors. We compared the effects of two angiogenesis inhibitors, TNP-470 and angiostatin, on slowly growing, poorly vascularized and rapidly growing, highly vascularized human tumors in mice. Methods: Slowly growing (RT-4) and rapidly growing (MGH-U1) human bladder carcinoma cell lines were grown in severe combined immunodeficiency mice. Established tumors were treated with one of the two angiogenesis inhibitors. Tumor volumes, vascularity, and proliferation indices were determined. The in vitro effects of TNP-470 and of angiostatin on the proliferation of RT-4 and MGH-U1 cells were also investigated. All statistical tests were two-sided. Results: RT-4 and MGH-U1 tumor growth was statistically significantly inhibited by both angiogenesis inhibitors (P<.001). Both inhibitors decreased the blood vessel density in both tumor types but did not alter the in vivo proliferation indices of the tumors. TNP-470, but not angiostatin, marginally decreased the in vitro proliferation of MGH-U1 cells. Conclusion: Slowly growing, poorly vascularized tumors in animal models respond as well as rapidly growing, highly vascularized tumors to therapy with the angiogenesis inhibitors TNP-470 and angiostatin.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  M Carvalho, L Mateus, F Afonso, S Van Harten, L Alfaro Cardoso, D A Redmer, and G Ferreira-Dias Testicular angiogenic activity in response to food restriction in rabbits Reproduction, March 1, 2009; 137(3): 509 - 515. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Ma and D. J. Waxman Dominant Effect of Antiangiogenesis in Combination Therapy Involving Cyclophosphamide and Axitinib Clin. Cancer Res., January 15, 2009; 15(2): 578 - 588. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Ma and D. J. Waxman Combination of antiangiogenesis with chemotherapy for more effective cancer treatment Mol. Cancer Ther., December 1, 2008; 7(12): 3670 - 3684. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. V. Kozin, F. Winkler, I. Garkavtsev, D. J. Hicklin, R. K. Jain, and Y. Boucher Human Tumor Xenografts Recurring after Radiotherapy Are More Sensitive to Anti-Vascular Endothelial Growth Factor Receptor-2 Treatment than Treatment-Naive Tumors Cancer Res., June 1, 2007; 67(11): 5076 - 5082. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. H. G. Hansma, H. J. Broxterman, I. van der Horst, Y. Yuana, E. Boven, G. Giaccone, H. M. Pinedo, and K. Hoekman Recombinant human endostatin administered as a 28-day continuous intravenous infusion, followed by daily subcutaneous injections: a phase I and pharmacokinetic study in patients with advanced cancer Ann. Onc., October 1, 2005; 16(10): 1695 - 1701. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. M. Bhujwalla, D. Artemov, K. Natarajan, M. Solaiyappan, P. Kollars, and P. E. G. Kristjansen Reduction of Vascular and Permeable Regions in Solid Tumors Detected by Macromolecular Contrast Magnetic Resonance Imaging after Treatment with Antiangiogenic Agent TNP-470 Clin. Cancer Res., January 1, 2003; 9(1): 355 - 362. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Hlatky, P. Hahnfeldt, and J. Folkman Clinical Application of Antiangiogenic Therapy: Microvessel Density, What It Does and Doesn't Tell Us J Natl Cancer Inst, June 19, 2002; 94(12): 883 - 893. [Full Text] [PDF]
|
|
|
|
|
|
O. Kisker, C. M. Becker, D. Prox, M. Fannon, R. D'Amato, E. Flynn, W. E. Fogler, B. K. L. Sim, E. N. Allred, S. R. Pirie-Shepherd, et al. Continuous Administration of Endostatin by Intraperitoneally Implanted Osmotic Pump Improves the Efficacy and Potency of Therapy in a Mouse Xenograft Tumor Model Cancer Res., October 1, 2001; 61(20): 7669 - 7674. [Abstract] [Full Text] [PDF]
|
|